INSERM U657, Université Victor Segalen Bordeaux2, Bordeaux Cedex, France.
Acta Psychiatr Scand. 2010 Jan;121(1):4-10. doi: 10.1111/j.1600-0447.2009.01425.x. Epub 2009 Jun 25.
To review findings from pharmaco-epidemiological studies exploring antipsychotic (AP) drugs prescribing trends.
We retrieved original studies that explored AP prescribing trends in general population samples since 2000. For each study, we extracted information on sampling method, period, assessment of AP use and corresponding estimates (incidence rates, prevalence rates, pharmacy sales, prescription data) and diagnostic assessment.
Nearly all studies meeting the inclusion criteria (n = 17) showed an increase in AP prescriptions, mainly because of a dramatic rise in second-generation antipsychotics (SGAP) prescriptions. APs are often prescribed for non-psychotic disorders in adults as well as in children and adolescents.
Considering the growing number of persons from the general population exposed to APs, population studies assessing the risk/benefit ratio of SGAP use in disorders other than psychosis are necessary, particularly in children and adolescents.
综述探索抗精神病药物(AP)处方趋势的药物流行病学研究结果。
我们检索了自 2000 年以来在一般人群样本中探索 AP 处方趋势的原始研究。对于每项研究,我们提取了有关采样方法、时间段、AP 使用评估以及相应估计(发病率、患病率、药房销售额、处方数据)和诊断评估的信息。
几乎所有符合纳入标准的研究(n = 17)都显示出 AP 处方的增加,主要是由于第二代抗精神病药物(SGAP)处方的急剧增加。AP 常用于治疗成年人的非精神病性疾病以及儿童和青少年的疾病。
考虑到越来越多的普通人群接触到 AP,需要进行评估除精神病以外的疾病中使用 SGAP 的风险/效益比的人群研究,特别是在儿童和青少年中。